PDF(Pubmed)
Abstract：
BACKGROUND: Immunoglobulin type A (IgA) nephropathy is the most common primary glomerulonephritis (GN) worldwide with higher rates in East and Pacific Asia compared to North America and Europe. Despite high reported prevalence of IgAN in these countries, the overall disease prevalence across Asia is not available. Treatment patterns of IgAN patients across Asian countries have also not been summarized. The aim of this study was to review and summarize evidence on IgA nephropathy prevalence, treatment patterns, and humanistic and economic burden in mainland China, Taiwan, South Korea, Japan, and Australia.
METHODS: A targeted literature review was conducted in PubMed and local databases in China (including Taiwan), South Korea, Japan, and Australia between January 2010-December 2021. Website literature searches were conducted using Google Scholar and Baidu.
RESULTS: Sixty-nine publications and 3 clinical guidelines were included. Incidence ranged from 0 to 10.7 per 100 000 people per year in Australia, Japan, and Taiwan, and ranged from 6.3 to 24.70% among patients who underwent renal biopsy in mainland China. Prevalence and diagnosis rates ranged from 0 to 72.1% in mainland China, South Korea, Taiwan, Japan, and Australia. Mortality rates in mainland China, South Korea, and Japan varied widely. The top 3 commonly used therapies were angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (0.9-99.6%), corticosteroids (3.5-100%), and immunosuppressants (1.6-85.5%) in Japan, mainland China, and South Korea. Patient quality of life was measured by different tools, and annual hospitalization costs ranged from $1 284.73 to $2 252.12 (2015-2018) in China.
CONCLUSIONS: The prevalence of IgA nephropathy among the general population in select countries/regions is not commonly available, despite evidence from studies and clinical guidelines. In addition, it is observed across geographic regions that heterogeneity exists in prevalence rates, and large variations exist in treatment patterns. There is need to fill in these gaps to understand the contributing factors behind the differences through population-based, multi-center, and real-world studies.
METHODS: A targeted literature review was conducted in PubMed and local databases in China (including Taiwan), South Korea, Japan, and Australia between January 2010-December 2021. Website literature searches were conducted using Google Scholar and Baidu.
RESULTS: Sixty-nine publications and 3 clinical guidelines were included. Incidence ranged from 0 to 10.7 per 100 000 people per year in Australia, Japan, and Taiwan, and ranged from 6.3 to 24.70% among patients who underwent renal biopsy in mainland China. Prevalence and diagnosis rates ranged from 0 to 72.1% in mainland China, South Korea, Taiwan, Japan, and Australia. Mortality rates in mainland China, South Korea, and Japan varied widely. The top 3 commonly used therapies were angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (0.9-99.6%), corticosteroids (3.5-100%), and immunosuppressants (1.6-85.5%) in Japan, mainland China, and South Korea. Patient quality of life was measured by different tools, and annual hospitalization costs ranged from $1 284.73 to $2 252.12 (2015-2018) in China.
CONCLUSIONS: The prevalence of IgA nephropathy among the general population in select countries/regions is not commonly available, despite evidence from studies and clinical guidelines. In addition, it is observed across geographic regions that heterogeneity exists in prevalence rates, and large variations exist in treatment patterns. There is need to fill in these gaps to understand the contributing factors behind the differences through population-based, multi-center, and real-world studies.
摘要：
背景：免疫球蛋白A型（IgA）肾病是全球最常见的原发性肾小球肾炎（GN），与北美和欧洲相比，东亚和太平洋地区的发病率更高。尽管在这些国家报告的IgAN患病率很高，整个亚洲的总体疾病患病率尚不清楚.亚洲国家IgAN患者的治疗模式也没有总结。这项研究的目的是回顾和总结有关IgA肾病患病率的证据。治疗模式,以及中国大陆的人文和经济负担，台湾,韩国,Japan,和澳大利亚。
方法：在PubMed和中国（包括台湾）的本地数据库中进行了有针对性的文献综述，韩国,Japan,和澳大利亚在2010年1月至2021年12月之间。使用GoogleScholar和百度进行网站文献检索。
结果：纳入了69篇出版物和3篇临床指南。澳大利亚每年每10万人的发病率为0至10.7，Japan,台湾,在中国大陆接受肾活检的患者中，占6.3％至24.70％。中国大陆的患病率和诊断率从0到72.1%不等,韩国,台湾,Japan,和澳大利亚。中国大陆的死亡率，韩国,日本差异很大。前3位的常用疗法为血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂(0.9-99.6%),皮质类固醇（3.5-100%），日本的免疫抑制剂（1.6-85.5%），中国大陆,和韩国。用不同的工具测量患者的生活质量，中国的年度住院费用为1284.73美元至2252.12美元(2015-2018年)。
结论：在某些国家/地区的普通人群中，IgA肾病的患病率并不常见，尽管有研究和临床指南的证据。此外,在不同地理区域观察到患病率存在异质性，治疗模式存在很大差异。有必要填补这些空白，通过以人口为基础，了解差异背后的促成因素，多中心,和现实世界的研究。
方法：在PubMed和中国（包括台湾）的本地数据库中进行了有针对性的文献综述，韩国,Japan,和澳大利亚在2010年1月至2021年12月之间。使用GoogleScholar和百度进行网站文献检索。
结果：纳入了69篇出版物和3篇临床指南。澳大利亚每年每10万人的发病率为0至10.7，Japan,台湾,在中国大陆接受肾活检的患者中，占6.3％至24.70％。中国大陆的患病率和诊断率从0到72.1%不等,韩国,台湾,Japan,和澳大利亚。中国大陆的死亡率，韩国,日本差异很大。前3位的常用疗法为血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂(0.9-99.6%),皮质类固醇（3.5-100%），日本的免疫抑制剂（1.6-85.5%），中国大陆,和韩国。用不同的工具测量患者的生活质量，中国的年度住院费用为1284.73美元至2252.12美元(2015-2018年)。
结论：在某些国家/地区的普通人群中，IgA肾病的患病率并不常见，尽管有研究和临床指南的证据。此外,在不同地理区域观察到患病率存在异质性，治疗模式存在很大差异。有必要填补这些空白，通过以人口为基础，了解差异背后的促成因素，多中心,和现实世界的研究。
